[Therapy with gestagens for gynecological tumors sensitive to hormones (author's transl)].
Our method of irradiation of the endometrial carcinoma is described. The patient collective concerned represents a negative selection, as only inoperable cases with an endometrial carcinoma undergo primary irradiation. The 5-year survival rate amounted to 50.4% of 802 patients in the period from 1950 through 1970. Additional therapy with gestagens is discussed and recommended. The histological alterations in the material obtained by so-called "second-look curettages" are reported. Application of gestagens to other hormonesensitive tumors such as carcinoma of the ovary or adenocarcinoma of the cervix uteri is considered.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans; D008535:Megestrol / Q000627:therapeutic use*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy; D010166:Palliative Care; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000532:radiotherapy
D008535:Megestrol
Gestagentherapie bei hormonsensitiven gynäkologischen Tumoren.